Intestinal Research

IBD
Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study: Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye, on behalf of the Korean Association for the Study of Intestinal Diseases; Intest Res. 2023;21(1):137-147. Published online July 12, 2022; DOI: https://doi.org/10.5217/ir.2021.00173
Web of Science 1 Crossref 1; Full text PubReader ePub PDF

Inflammatory Bowel Diseases
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI): Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, Yoshifumi Ohnishi, Noriyuki Fujii, Nobuko Matsushima, Richuan Zheng, Colleen W. Marano; Intest Res. 2021;19(4):386-397. Published online December 1, 2020; DOI: https://doi.org/10.5217/ir.2020.00080
Web of Science 16 Crossref 16; Full text PubReader ePub PDF Supplementary Material

Inflammatory bowel diseases
Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria: Sadik Saman, Martin Goetz, Judith Wendler, Nisar P. Malek, Jan Wehkamp, Thomas Klag; Intest Res. 2019;17(3):340-348. Published online May 31, 2019; DOI: https://doi.org/10.5217/ir.2019.00012
Web of Science 14 Crossref 18; Full text PubReader ePub PDF

Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies: Toshifumi Hibi, Yuya Imai, Yoko Murata, Nobuko Matsushima, Richuan Zheng, Christopher Gasink; Intest Res. 2017;15(4):475-486. Published online October 23, 2017; DOI: https://doi.org/10.5217/ir.2017.15.4.475
Web of Science 18 Crossref 20; Full text PubReader ePub PDF Supplementary Material

Search